PURPOSE: The narrow efficacy-toxicity window of anticancer agents necessitates understanding of factors contributing to their disposition. This is especially true for camptothecins as they exist in the lactone and carboxylate forms with each moiety differentially interacting with efflux or uptake transporters. Here we determined the disposition of the lactone and carboxylate forms of AR-67, a 3(rd) generation camptothecin analogue. METHODS: Pharmacokinetic studies were conducted in rats given intravenous boluses of AR-67 lactone or carboxylate with or without pharmacologic inhibitor pretreatment (GF120918 or rifampin). Pharmacokinetic modeling was used to estimate clearances, while simulations assessed the impact of clearance changes on overall AR-67 exposure. RESULTS: Our modeling showed that carboxylate clearance was 3.5-fold higher than that of the lactone. GF120918 decreased lactone clearance only, but rifampin decreased both lactone and carboxylate clearances. Simulations showed that decreasing carboxylate clearance, which controls the overall drug disposition, leads to significant increase in AR-67 exposure. CONCLUSION: The apparent in vivo blood stability of AR-67 is partly dependent on the increased carboxylate clearance. This may have clinical implications for populations with single nucleotide polymorphisms that impair the function of uptake transporter genes (e.g., SLCO1B1), which are potentially responsible for AR-67 carboxylate clearance.
PURPOSE: The narrow efficacy-toxicity window of anticancer agents necessitates understanding of factors contributing to their disposition. This is especially true for camptothecins as they exist in the lactone and carboxylate forms with each moiety differentially interacting with efflux or uptake transporters. Here we determined the disposition of the lactone and carboxylate forms of AR-67, a 3(rd) generation camptothecin analogue. METHODS: Pharmacokinetic studies were conducted in rats given intravenous boluses of AR-67 lactone or carboxylate with or without pharmacologic inhibitor pretreatment (GF120918 or rifampin). Pharmacokinetic modeling was used to estimate clearances, while simulations assessed the impact of clearance changes on overall AR-67 exposure. RESULTS: Our modeling showed that carboxylate clearance was 3.5-fold higher than that of the lactone. GF120918 decreased lactone clearance only, but rifampin decreased both lactone and carboxylate clearances. Simulations showed that decreasing carboxylate clearance, which controls the overall drug disposition, leads to significant increase in AR-67 exposure. CONCLUSION: The apparent in vivo blood stability of AR-67 is partly dependent on the increased carboxylate clearance. This may have clinical implications for populations with single nucleotide polymorphisms that impair the function of uptake transporter genes (e.g., SLCO1B1), which are potentially responsible for AR-67 carboxylate clearance.
Authors: E A Natelson; B C Giovanella; C F Verschraegen; K M Fehir; P D De Ipolyi; N Harris; J S Stehlin Journal: Ann N Y Acad Sci Date: 1996-12-13 Impact factor: 5.691
Authors: Serena Marchetti; Roos L Oostendorp; Dick Pluim; Monique van Eijndhoven; Olaf van Tellingen; Alfred H Schinkel; Richard Versace; Jos H Beijnen; Roberto Mazzanti; Jan H Schellens Journal: Mol Cancer Ther Date: 2007-12 Impact factor: 6.261
Authors: Anita K Lalloo; Feng R Luo; Ailan Guo; Pankaj V Paranjpe; Sung-Hack Lee; Viral Vyas; Eric Rubin; Patrick J Sinko Journal: BMC Med Date: 2004-05-04 Impact factor: 8.775
Authors: T P Sajitha; B L Manjunatha; R Siva; Navdeep Gogna; Kavita Dorai; G Ravikanth; R Uma Shaanker Journal: J Chem Ecol Date: 2018-05-25 Impact factor: 2.626